{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:04:43Z","timestamp":1784189083630,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":998,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.14283\/jpad.2021.54","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T03:23:52Z","timestamp":1631503432000},"page":"92-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Ups and Downs of Amyloid in Alzheimer's"],"prefix":"10.1016","volume":"9","author":[{"given":"E.","family":"Siemers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.S.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2021.54_bib1","unstructured":"Fukumoto H A-OA, Suzuk N, Shimada H, Ihara Y, Iwatsubo T. Amyloid Beta Protein Deposition in Normal Aging Has the Same Characteristics as That in Alzheimer's Disease. American Journal of Pathology;148(1):259\u2013265."},{"issue":"2","key":"10.14283\/jpad.2021.54_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"The Lancet Neurology"},{"issue":"9","key":"10.14283\/jpad.2021.54_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.14283\/jpad.2021.54_bib4","first-page":"180","article-title":"Commentary: Combination Therapy for Alzheimer's Disease: Perspectives of the EU\/US CTAD Task Force","volume":"6","author":"Siemers","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"10.14283\/jpad.2021.54_bib5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jalz.2016.02.007","article-title":"Challenges, solutions, and recommendations for Alzheimer's disease combination therapy","volume":"12","author":"Hendrix","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.14283\/jpad.2021.54_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"44","key":"10.14283\/jpad.2021.54_bib7","doi-asserted-by":"crossref","first-page":"29627","DOI":"10.1074\/jbc.R800010200","article-title":"Intramembrane proteolysis by gamma-secretase","volume":"283","author":"Steiner","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"10.14283\/jpad.2021.54_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.21623","article-title":"A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system","volume":"66","author":"Bateman","year":"2009","journal-title":"Ann Neurol"},{"issue":"4","key":"10.14283\/jpad.2021.54_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.14283\/jpad.2021.54_bib10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch Neurol"},{"issue":"7409","key":"10.14283\/jpad.2021.54_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.14283\/jpad.2021.54_bib12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14737175.2019.1621751","article-title":"Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?","volume":"19","author":"Panza","year":"2019","journal-title":"Expert Rev Neurother"},{"issue":"7618","key":"10.14283\/jpad.2021.54_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.14283\/jpad.2021.54_bib14","first-page":"255","article-title":"Clinical Development of Aducanumab, an Anti-Abeta Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease","volume":"4","author":"Budd Haeberlein","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2021.54_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility","author":"Alexander","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.14283\/jpad.2021.54_bib16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"key":"10.14283\/jpad.2021.54_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","author":"Mintun","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.14283\/jpad.2021.54_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"issue":"1","key":"10.14283\/jpad.2021.54_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2021.54_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.14283\/jpad.2021.54_bib21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12168","article-title":"Amyloid-ss-directed immunotherapy for Alzheimer's disease","volume":"275","author":"Lannfelt","year":"2014","journal-title":"J Intern Med"},{"issue":"1","key":"10.14283\/jpad.2021.54_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer's Research & Therapy"},{"issue":"4","key":"10.14283\/jpad.2021.54_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"The Lancet Neurology"},{"issue":"3","key":"10.14283\/jpad.2021.54_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.14283\/jpad.2021.54_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"24","key":"10.14283\/jpad.2021.54_bib26","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"10.14283\/jpad.2021.54_bib27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.14283\/jpad.2021.54_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer's disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.14283\/jpad.2021.54_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","article-title":"Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease","volume":"33","author":"Siemers","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.14283\/jpad.2021.54_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.14283\/jpad.2021.54_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.14283\/jpad.2021.54_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"28","key":"10.14283\/jpad.2021.54_bib33","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","article-title":"An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta","volume":"32","author":"Adolfsson","year":"2012","journal-title":"J Neurosci"},{"issue":"21","key":"10.14283\/jpad.2021.54_bib34","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.14283\/jpad.2021.54_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2021.54_bib36","doi-asserted-by":"crossref","first-page":"39374","DOI":"10.1038\/srep39374","article-title":"Structure of Crenezumab Complex with Abeta Shows Loss of beta-Hairpin","volume":"6","author":"Ultsch","year":"2016","journal-title":"Sci Rep"},{"issue":"s1","key":"10.14283\/jpad.2021.54_bib37","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade","volume":"64","author":"Cline","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"Supplement 1","key":"10.14283\/jpad.2021.54_bib38","first-page":"S151","article-title":"Synaptic intervention in alzheimer's disease: soluble a\u03b2 oligomer directed ACU193 monoclonal antibody therapeutic for treatment of early alzheimer's disease","volume":"6","author":"Cline","year":"2019","journal-title":"J Prevent Alzheimer's Dis"},{"issue":"1","key":"10.14283\/jpad.2021.54_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","article-title":"On the path to 2025: understanding the Alzheimer's disease continuum","volume":"9","author":"Aisen","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"111","key":"10.14283\/jpad.2021.54_bib40","doi-asserted-by":"crossref","first-page":"111c","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.14283\/jpad.2021.54_bib41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel","volume":"316","author":"Gunthard","year":"2016","journal-title":"JAMA"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:44:50Z","timestamp":1736469890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724003650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2274580724003650"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2021.54","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Ups and Downs of Amyloid in Alzheimer's","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2021.54","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}